A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 599 participants.

Also called NCT01624259

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 599 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01624259
  • EudraCT 2011-003810-18
Other papers using this trial's data
  • Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet (London, England), 2014-10-11 DOI, PubMed 25018121

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Germany, Hungary, Mexico, Poland, Puerto Rico, Romania, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01624259. Randomized; no masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-11 (actual). Results posted on 2014-10-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
Acronym
AWARD-6
Intervention (Drug)
LY2189265
Intervention (Drug)
Liraglutide
Intervention (Drug)
Metformin
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01624259
Content hash
d045b96823f367b7c12b83aab9f5f756e3fd9e30dd68df542d2f9d6922188476